Rani Therapeutics Holdings, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Samsara BioCapital and its affiliates have increased their beneficial ownership in Rani Therapeutics through a $2 million registered direct offering.
NASDAQ
Samsara BioCapital entities invest $12 million in Rani Therapeutics through a private placement, gaining a board seat and influencing significant governance changes.
NASDAQ
Mir Imran, a key insider, increased his stake in Rani Therapeutics through a private placement, alongside proposed significant corporate governance changes.
NASDAQ
South Lake Management and its affiliates have reduced their beneficial ownership in Rani Therapeutics Holdings, Inc. to below 5% through recent open-market sales.